Reductions in stavudine dose might ameliorate mitochondrial-associated complications without compromising antiviral activity

HIV Clinical Trials

Volumn 6, Issue 4, 2005, Pages 197-202

  Sánchez Conde, Matilde ^a   de Mendoza, Carmen ^a   Jiménez Nacher, Immaculada ^a   Barreiro, Pablo ^a   Gonzales Lahoz, Juan ^a   Soriano, Vincent ^a  

^a HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

Author keywords

Lipoatrophy; Mitochondrial toxicity; Stavudine

Indexed keywords

ABACAVIR; ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CHOLESTEROL; DIDANOSINE; EFAVIRENZ; LACTIC ACID; LAMIVUDINE; LOPINAVIR; MITOCHONDRIAL DNA; NEVIRAPINE; PROTEINASE INHIBITOR; STAVUDINE; TENOFOVIR; TRIACYLGLYCEROL; VIRUS RNA;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIVIRAL ACTIVITY; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DNA CONTENT; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG SAFETY; FEMALE; FOLLOW UP; HEPATITIS C; HEPATITIS C VIRUS; HIV ASSOCIATED LIPODYSTROPHY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LACTATE BLOOD LEVEL; LIPOATROPHY; MAJOR CLINICAL STUDY; MALE; MITOCHONDRIAL DNA DEPLETION; MITOCHONDRIAL TOXICITY; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; SUPERINFECTION; TREATMENT FAILURE; TRIACYLGLYCEROL BLOOD LEVEL;

CASE-CONTROL STUDIES; DNA, MITOCHONDRIAL; DRUG ADMINISTRATION SCHEDULE; FEMALE; HIV INFECTIONS; HUMANS; LEUKOCYTES, MONONUCLEAR; MALE; REVERSE TRANSCRIPTASE INHIBITORS; STAVUDINE; VIRAL LOAD;

EID: 27744498063     PISSN: 15284336     EISSN: None     Source Type: Journal    
DOI: 10.1310/ED57-EU48-RK6A-E5U0     Document Type: Article

References (33)

1. Stavudine approved under accelerated drug-approval process. Am J Hosp Pharm. 1994;51:2087-2091.
2. Hurst M, Noble S. Stavudine: an update of it use in the treatment of HIV infection. Drugs. 1999;58:919-949.
3. Saint-Marc T, Partisani M, Poizot-Martin I, et al. A syndrome of peripheral fat wasting (lipodystrophy) in patients receiving long-term nucleoside analogue therapy. AIDS. 1999;13:1659-1667.
4. Mallal S, John M, Moore C, James I, McKinnon E. Contribution of nucleoside analogue reverse transcriptase inhibitors to subcutaneous fat wasting in patients with HIV infection. AIDS. 2000;14:1309-1316.
5. Carr A, Miller J, Law M, Cooper D. A syndrome of lipoatrophy, lactic acidaemia and liver dysfunction associated with HIV nucleoside analogue therapy: contribution to protease inhibitor related lipodystrophy syndrome. AIDS. 2000;14:F25-F32.
6. van der Valk M, Casula M, Weverlingz G, et al. Prevalence of lipoatrophy and mitochondrial DNA content of blood and subcutaneous fat in HIV-1-infected patients randomly allocated to zidovudine- or stavudine-based therapy. Antivir Ther. 2004;9:385-393.
7. Bogner J, Vielhauer V, Beckmann R, et al. Stavudine versus zidovudine and the development of lipodystrophy. J Acquir Immune Defic Syndr. 2001;27:237-244.
8. Martinez E, Mocroft A, Garcia-Viejo MA, et al. Risk of lipodystrophy in HIV-1-infected patients treated with protease inhibitors: a prospective cohort study. Lancet. 2001;357:592-598.
9. Mokrzycki M, Harris C, May H, Laut J, Palmisano J. Lactic acidosis associated with stavudine administration: a report of five cases. Clin Infect Dis. 2000,30:198-200.
10. Garcia-Benayas T, Blanco F, de la Cruz J, et al. Replacing stavudine by abacavir reduces lactate levels and may improve lipoatrophy. AIDS. 2003;17:921-924.
11. Martin A, Smith D, Carr A, et al. Reversibility of lipoatrophy in HIV-infected patients 2 years after switching from a thymidine analogue to abacavir: the MITOX Extension Study. AIDS. 2004;18:1029-1036.
12. Lafeuillade A, Jolly P, Chadapaud S, Hittinger G, Lambry V, Philip G. Evolution of lipid abnormalities in patients switched from stavudine- to tenofovir-containing regimens. J Acquir Immun Defic Syndr. 2003;33:544-546.
13. Milinkovic A, Lopez S, Vidal S, et al. A randomized open study comparing the effect of reducing stavudine dose vs switching to tenofovir on mitochondrial function, metabolic parameters, and subcutaneous fat in HIV-infected patients receiving antiretroviral therapy containing stavudine. Presented at: 12th Conference on Retroviruses and Opportunistic Infections; February 22-25, 2005; Boston, Massachusetts. Abstract 857.
14. Holguin A, Dietrich U, Immelmann A, Soriano V. Genotypic and phenotypic resistance to stavudine after long-term monotherapy. BMS-020 Spanish Study Group. Antivir Ther. 1998,3:183-186.
15. Lafeuillade A, Tardy J. Stavudine in the face of cross-resistance between HIV-1 nucleoside reverse transcriptase inhibitors: a review. AIDS Rev. 2003;5:80-86.
16. Bocket L, Yazdanpanah Y, Ajana F, et al. Thymidine analogue mutations in antiretroviral-naive HIV-1 patients on triple therapy including either zidovudine or stavudine. J Antimicrob Chemother. 2004;53:89-94.
17. Villalba N, Soriano V, Gomez-Cano M, Castilla J, Mas A, Gonzalez-Lahoz J. Short-term efficacy and safety of stavudine in pretreated HIV infected patients. Antivir Ther. 1997;2:185-189.
18. Laurent C, Kouanfack C, Koulla-Shiro S, et al. Effectiveness and safety of a generic fixed-dose combination of nevirapine, stavudine and lamivudine in HIV-1-infected adults in Cameroon: open-label multicentre trial. Lancet. 2004;364:29-34.
19. Kakuda T. Pharmacology of nucleoside and nucleotide reverse transcriptase inhibitor-induced mitochondrial toxicity. Clin Ther. 2000;22:685-708.
20. de Mendoza C, de Ronde A, Smolders K, et al. Changes in mitochondrial DNA copy number in blood cells from HIV-infected patients undergoing antiretroviral therapy. AIDS Res Hum Retroviruses. 2004;20:271-273.
21. van der Valk M, Casula M, Weverlingz G, et al. Prevalence of lipoatrophy and mitochondrial DNA content of blood and subcutaneous fat in HIV-1-infected patients randomly allocated to zidovudine- or stavudine-based therapy. Antivir Ther. 2004;9:385-393.
22. Barreiro P, Garcia-Benayas T, Rendon A, Rodriguez-Novoa S, Soriano V. Combinations of nucleoside/nucleotide analogues for HIV therapy. AIDS Rev. 2004;6:234-243.
23. Hanvanich M, et al. Reduction of d4T improves lipoatrophy without virologic failure. Presented at: 2nd IAS Conference; 2003; Paris. Abstract 749.
24. Dudley M, Graham K, Kaul S, et al. Pharmacokinetics of stavudine in patients with AIDS or AIDS-related complex. J Infect Dis. 1992;166:480-485.
25. Fisher M. Nucleoside combinations for antiretroviral therapy: efficacy of stavudine in combination with either didanosine or lamivudine. AIDS. 1998;12(suppl):9-16.
26. Yeni P, Hammer S, Hirsch M, et al. Treatment for adult HIV infection: 2004 recommendations of the International AIDS Society-USA Panel. JAMA. 2004;292:266-268.
27. Dybul M, Fauci A, Bartlett J, et al. Guidelines for using antiretroviral agents among HIV-infected adults and adolescents. Ann Intern Med. 2002;137:381-433.
28. Fischl M, Parker C, Pettinelli C, et al. A randomized controlled trial of a reduced daily dose of zidovudine in patients with the acquired immunodeficiency syndrome. N Engl J Med. 1990;323:1009-1014.
29. Koegl C. Low dose stavudine: as effective as standard dose but less side effects. Presented at: 9th European AIDS Conference; 2003; Warsaw. Abstract 9.8/5.
30. del Pierre C. Lowering stavudine dosages does not compromise antiviral efficacy in HIV-infected patients. Presented at: 9th European AIDS Conference; 2003; Warsaw. Abstract 9.4/2.
31. Skowron G. Biologic effects and safety of stavudine: overview of phase I and II clinical trials. J Infect Dis. 1995;171(suppl 2):113-117.
32. Petersen E, Ramirez-Ronda C, Hardy W, et al. Dose-related activity of stavudine in patients infected with HIV. J Infect Dis. 1995;171(suppl 2):131-139.
33. Cote H, Brumme Z, Craib K, et al. Changes in mitochondrial DNA as a marker of nucleoside toxicity in HIV-infected patients. N Engl J Med. 2002;346:811-820.